Regeneron Pharmaceuticals Inc $ 620.86 -19.77 (-3.09%)
Volume:
926,292
Avg Vol (1m):
1,509,742
Market Cap $:
63.70 Bil
Enterprise Value $:
60.41 Bil
P/E (TTM):
31.20
P/B:
5.74
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 5.6 | ||
| Equity-to-Asset | 0.77 | ||
| Debt-to-Equity | 0.06 | ||
| Debt-to-EBITDA | 0.26 | ||
| Interest Coverage | 84.96 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 12.8 | ||
| Beneish M-Score | -2.4 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 30.45 | ||
| Net Margin % | 28.56 | ||
| ROE % | 21.53 | ||
| ROA % | 16.16 | ||
| ROC (Joel Greenblatt) % | 50.84 | ||
| 3-Year Revenue Growth Rate | 18 | ||
| 3-Year EBITDA Growth Rate | 23.4 | ||
| 3-Year EPS without NRI Growth Rate | 33.8 |
Valuation Rank | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 31.2 | ||
| Forward PE Ratio | 24.04 | ||
| PE Ratio without NRI | 31.2 | ||
| Price-to-Owner-Earnings | 54.81 | ||
| PB Ratio | 5.74 | ||
| PS Ratio | 8.91 | ||
| Price-to-Free-Cash-Flow | 41.69 | ||
| Price-to-Operating-Cash-Flow | 31.88 | ||
| EV-to-EBIT | 23.41 | ||
| EV-to-EBITDA | 21.61 | ||
| EV-to-Revenue | 7.57 | ||
| PEG Ratio | 1.16 | ||
| Shiller PE Ratio | 76.09 | ||
| Current Ratio | 4.21 | ||
| Quick Ratio | 3.49 | ||
| Days Inventory | 602.18 | ||
| Days Sales Outstanding | 115.79 | ||
| Days Payable | 154.76 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.74 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.54 | ||
| Price-to-Median-PS-Value | 0.85 | ||
| Price-to-Peter-Lynch-Fair-Value | 1.3 | ||
| Price-to-Graham-Number | 2.82 | ||
| Earnings Yield (Greenblatt) % | 4.27 | ||
| Forward Rate of Return (Yacktman) % | 21.86 |